UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event
reported)
|
November 5,
2016
|
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34th St.
|
|
Orlando,
FL
|
32811
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On November 5, 2016, the
Board of Directors (the “Board”) of MEDITE Cancer
Diagnostics, Inc. (the “Company”) held a meeting
whereby it terminated the employment of Robert F. McCullough Jr. as
Chief Financial Officer, Secretary and Treasurer of the Company. As
of the date hereof, Mr. McCullough remains a Director of the
Company. The Company is undertaking a search for qualified
candidates to fill the Chief Financial Officer
position.
Item 9.01
Financial
Statements and Exhibits
None.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE CANCER
DIAGNOSTICS, INC.
|
|
|
|
|
|
|
Date: November 8,
2016
|
By:
|
/s/
David Patterson
|
|
|
|
David
Patterson
|
|
|
|
Chief Executive Officer |
|
|